Avanti Polar Lipids (CRDA)

Executive Summary

Avanti Polar Lipids (now Avanti Research), a Croda brand, is a leading supplier of high-purity lipids and lipid nanoparticle (LNP) technologies essential for drug delivery and biologics. Founded in 1967 and based in Alabaster, Alabama, the company provides critical raw materials for research and commercial production, including ionizable lipids, phospholipids, and PEGylated lipids. Its lipids were integral to the success of mRNA COVID-19 vaccines and are foundational for emerging therapeutics such as gene editing, cancer vaccines, and protein replacement therapies. As a strategic supplier, Avanti benefits from the expanding LNP market, driven by growing demand for non-viral delivery systems across multiple therapy areas. Growth prospects are supported by continuous innovation in lipid design, expansion of custom synthesis capabilities, and collaboration with pharmaceutical partners to scale novel LNP formulations. The company's established infrastructure and Croda's global resources position it to capture increasing demand as LNP-based drugs progress through clinical trials. Key upcoming catalysts include the expansion of its lipid portfolio for next-generation LNP applications, potential long-term supply agreements with major biotech firms, and FDA approvals of drugs that rely on its proprietary lipids, which could drive revenue growth and market share gains.

Upcoming Catalysts (preview)

• Q3 2026Expansion of novel ionizable lipid library for gene editing and RNA therapeutics80% success
• Q4 2026Commercial supply agreement with a major biotech for LNP-based therapy65% success
• Q1 2027FDA approval of a drug using Avanti's lipids as key excipient50% success